Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00047) | |||||
---|---|---|---|---|---|
Name |
Atazanavir
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Atazanavir; 198904-31-3; Latazanavir; Reyataz; Zrivada; BMS-232632; CGP 73547; BMS 232632; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; Reyataz (TN); CHEMBL1163; QZU4H47A3S; CHEBI:37924; NCGC00182552-01; Atazanavir [INN:BAN]; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; atazanavirum; 1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate; Atazanavir (INN); methyl N-[(1S)-1-[[(1S,2S)-1-benzyl-2-hydroxy-3-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethyl-butanoyl]amino]-[[4-(2-pyridyl)phenyl]methyl]amino]propyl]carbamoyl]-2,2-dimethyl-propyl]carbamate; methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; CAS-198904-31-3; HSDB 7339; Reyataz(TM) (*1:1 sulfate*); PubChem22425; ATV & AAG; ATV & HSA; SCHEMBL41696; cc-607; ATAZANAVIR,BISULFATESALT; Atazanavir, >=98% (HPLC); DTXSID9048691; Atazanavir & human serum albumin; BDBM13934; GTPL11138; AOB5590; HMS2089P22; ACT06755; Atazanavir(BMS-232632)/Reyataz; ZINC3941496; Tox21_113081; ABP000606; CA0144; MFCD08435966; Atazanavir & alpha1-acid glycoprotein; AKOS025396423; Tox21_113081_1; CCG-270390; CS-0945; DB01072; SB19156; NCGC00182552-02; NCGC00182552-03; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide; 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S-(3R*,8R*,9R*,12R*))-; BS-16315; dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; HY-17367; methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-dimethylpropyl]carbamate; AB0073035; A25022; D07471; S-7876; AB01274792-01; AB01274792-02; AB01274792-03; AB01274792_04; 114589-EP2272830A1; 114589-EP2298783A1; Q423467; SR-01000930924; J-519602; SR-01000930924-2; 6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,; 3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (3s,8s,9s,12s)-2,5,6,10,13-pentaazatetradecanedioic acid; Atazanavir;(2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide; methyl [(1S,4S,5S,10S)-4-benzyl-1,10-di-tert-butyl-5-hydroxy-2,9,12-trioxo-7-(4-pyridin-2-ylbenzyl)-13-oxa-3,7,8,11-tetraazatetradec-1-yl]carbamate (non-preferred name); methyl N-[(1S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethyl-butanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenyl-butan-2-yl]carbamoyl]-2,2-dimethyl-propyl]carbamate; methyl N-[(1S)-1-{[(2S,3S)-3-hydroxy-4-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-N''-{[4-(pyridin-2-yl)phenyl]methyl}butanehydrazido]-1-phenylbutan-2-yl]carbamoyl}-2,2-dimethylpropyl]carbamate; Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]ami
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Human immunodeficiency virus infection | ICD-11: 1C60 | [1] | ||
PubChem CID | |||||
Formula |
C38H52N6O7
|
||||
Canonical SMILES |
CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
|
||||
InChI |
1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
|
||||
InChIKey |
AXRYRYVKAWYZBR-GASGPIRDSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=148192"></iframe>
|
||||
3D MOL is unavailable | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 704.9 | Topological Polar Surface Area | 171 | |
XlogP | 5.6 | Complexity | 1110 | ||
Heavy Atom Count | 51 | Rotatable Bond Count | 18 | ||
Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 9 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Atazanavir 150 mg capsule | Click to Show/Hide the Full List of Formulation(s): 3 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Butyl alcohol; Fd&c blue no. 2; Isopropyl alcohol; Magnesium stearate; Ammonia; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Crospovidone; Alcohol; Gelatin; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Physicians Total Care; RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Butyl alcohol; Fd&c blue no. 2; Isopropyl alcohol; Magnesium stearate; Ammonia; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Alcohol; Crospovidone (15 mpa.s at 5%); Gelatin; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Avera McKennan Hospital | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Butyl alcohol; Fd&c blue no. 2; Isopropyl alcohol; Magnesium stearate; Ammonia; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Alcohol; Crospovidone (15 mpa.s at 5%); Gelatin, unspecified; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | E.R. Squibb & Sons; RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Atazanavir 200 mg capsule | Click to Show/Hide the Full List of Formulation(s): 3 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Butyl alcohol; Fd&c blue no. 2; Isopropyl alcohol; Magnesium stearate; Ammonia; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Crospovidone; Alcohol; Gelatin; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | A-S Medication Solutions; Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Butyl alcohol; Fd&c blue no. 2; Isopropyl alcohol; Magnesium stearate; Ammonia; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Alcohol; Crospovidone (15 mpa.s at 5%); Gelatin; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Avera McKennan Hospital | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Butyl alcohol; Fd&c blue no. 2; Isopropyl alcohol; Magnesium stearate; Ammonia; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Alcohol; Crospovidone (15 mpa.s at 5%); Gelatin, unspecified; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | A-S Medication Solutions; E.R. Squibb & Sons; RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Atazanavir 300 mg capsule | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Butyl alcohol; Fd&c blue no. 2; Isopropyl alcohol; Magnesium stearate; Ammonia; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Crospovidone; Alcohol; Gelatin; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | A-S Medication Solutions; Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Butyl alcohol; Fd&c blue no. 2; Isopropyl alcohol; Magnesium stearate; Ammonia; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Alcohol; Crospovidone (15 mpa.s at 5%); Gelatin, unspecified; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | A-S Medication Solutions; E.R. Squibb & Sons; RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [2] | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [3] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.